Roman Butler Fullerton & CO Biomarin Pharmaceutical Inc Transaction History

Roman Butler Fullerton & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 27, 2023	SELL	$87.74 - $117.27 $333,061 - $445,156	-3,796 Reduced 25.93%	10,841 $1.05 Million
Q4 2022 Jan 23, 2023	BUY	$80.93 - $108.63 $182,578 - $245,069	2,256 Added 18.22%	14,637 $0
Q3 2022 Oct 17, 2022	BUY	$82.16 - $96.94 $165,881 - $195,721	2,019 Added 19.48%	12,381 $1.09 Million
Q2 2022 Jul 26, 2022	BUY	$71.48 - $86.85 $740,675 - $899,939	10,362 New	10,362 $902,000
Q3 2020 Oct 15, 2020	SELL	$71.87 - $131.03 $545,133 - $993,862	-7,585 Closed	0 $0
Q2 2020 Jul 28, 2020	SELL	$79.55 - $124.22 $63,083 - $98,506	-793 Reduced 9.47%	7,585 $936,000
Q1 2020 Apr 13, 2020	BUY	$71.37 - $96.85 $597,937 - $811,409	8,378 New	8,378 $708,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Roman Butler Fullerton & CO, based on Form 13F filings with the SEC.

Stay updated on Roman Butler Fullerton & CO with notifications on news.